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A 79-year-old man with a past medical history of diet-
controlled type 2 diabetes mellitus, hypertension, and
chronic lower extremity venous stasis ulcers requiring two
skin grafts was admitted to the hospital due to dehydra-
tion. He was in his usual state of health of intermittently
being wheelchair bound due to leg ulcers until four days
earlier, when he accidentally spilled hot tea on his left arm
while in the kitchen. In his attempt to maneuver the
wheelchair away from the spill, the wheelchair turned
over, pinning him on the floor and against the cabinets.
He remained in that position for four days until he was
found by a neighbor in semi-conscious state lying in urine
and feces. The patient was agitated and combative when
aroused and was transported to the emergency room.
Upon questioning in the emergency room, the patient
stated that he had not hit his head during the fall, but
did hurt his back. He denied any recent fevers, chills,
sweats, weight loss, chest pain, shortness of breath,
abdominal pain, dysuria, hematuria, nausea, vomiting,
diarrhea, or melena. The patient reported that his diabetes
and hypertension had been well controlled, however, he
does not check his blood glucose or blood pressure at
home. The patient denied any allergies to medications.
His medication list included hydralazine, glipizide,
chlorthalidone, and a multivitamin every day. He denied
any tobacco use, as well as illicit drug use. He consumed
minimal alcohol. The patient had no knowledge of his
family medical history.
On physical examination, the patient appeared confused
and mildly uncomfortable. His temperature was 96.5
degrees Fahrenheit, blood pressure of 172/90 mm/Hg,
pulse of 74 bpm, and respiratory rate of 20. His oxygen
saturation was 96 % on room air. Pupils were equal and
reactive and no nystagmus was seen. Cardiac and abdom-
inal exam were normal. There were decreased breath at
the bases bilaterally, but with poor inspiratory effort.
There was mild gynecomastia, but no lymphadenopathy.
A stage I sacral decubitus ulcer measuring 2 cm by 4 cm
was noted. There was no costovertebral angle tenderness,
however, there was lumber spine tenderness. Lower
extremities were without clubbing or edema, with strong
distal pulses. Skin exam revealed venous stasis changes of
the lower extremities. Prior skin graft donor sites were
seen on the anterior thighs bilaterally. Neurologic exami-
nation was difficult due to the patient’s poor cooperative
effort. Cranial nerve exam revealed weak abduction of the
left eye. His speech was slurred. Muscle tone was noted to
be slightly rigid, with generalized 4/5 strength. The
patient had cogwheeling of his upper extremities as well
as a resting tremor. Sensation was intact. Biceps and patel-
lar reflexes were 1+ bilaterally, however four beat clonus
was appreciated in the feet. Babinski reflexes were absent.
Gait could not be assessed. Mini-mental status examina-
tion with a score of 17/30 was obtained. The patient was
unable to perform serial sevens, recall three words after
three minutes, and write or draw sufficiently. 
Laboratory work-up revealed an elevated white blood cell
count (WBC) of 16,000 ml3, with a neutrophil count of
96%. His hemoglobin, platelet count, prothrombin time
and partial thromboplastin time were all within normal
limits. His blood urea nitrogen (BUN) was elevated to 57
mg/dL and had a creatinine of 1.9 mg/dL. Total calcium
was elevated at 14.2 mg/dL. Intact parathyroid hormone
(PTH) was low at 6 pg/ml, and PTH-related peptide
(PTH-rP) was elevated at 3.6 pmol/L. His CPK was ele-
vated to 3,555 IU/L, with a CK-MB of 24.2 ng/ml.
Myoglobin was also elevated at 9,771 ng/ml. His AST
was high at 123 IU/L, with the remainder of the liver
function tests being normal. Urinalysis showed 2+ blood,
1+ ketones, 2 white blood cells/hpf, 5 red blood cells/hpf,
2+ bacteria. The remainder of his chemistries, TSH, and
PSA were normal
Posteroanterior and lateral chest radiographs revealed a
right subpulmonic pleural effusion. Spinal series radi-
ographs revealed degenerative disk disease without frac-
tures. A computed tomographic (CT) scan of the head
without intravenous contrast revealed disproportionate
enlargement of the ventricles as compared to the sulci,
and mild general volume loss. No hemorrhage, infarct, or
other acute changes were seen. A CT scan of the thorax
without intravenous contrast was performed (Figures 1
and 2), which demonstrated a right pleural effusion,
bibasilar atelectasis, and multiple bilateral lung nodules
5 to 10 mm seen in all lung lobes. There were no enlarged
hilar or mediastinal lymph nodes, but there was some
right hilar nodal calcification. A nodular infiltrative soft
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tissue mass was seen in the superior aspect of the right
retroperitoneal space, involving both the right adrenal
gland and kidney. The mass extended into the right
perirenal space, inferior right pleural space, and posterior
right flank. The spleen, liver, and left adrenal gland were
unremarkable. No lytic bone lesions were observed. The
left kidney was not visualized. 
The patient was treated for acute symptomatic hypercal-
cemia. An ultrasound guided fine needle aspiration of the
right kidney mass was performed. Thirty milliliters of
bloody fluid was obtained. Microscopic examination of
the specimen revealed malignant neoplastic epithelial
cells with focal spindle features consistent with renal cell
carcinoma. He was diagnosed with Stage IV renal cell car-
cinoma with mixed with sarcomatoid features.
Discussion
The differential diagnosis for this patient was initially made
for acute symptomatic hypercalcemia. When the CT scan
of the thorax was performed the differential diagnosis was
narrowed to include concomitant retroperitoneal and pul-
monary masses, although the possibility the masses were
unrelated to the hypercalcemia could not be disregarded.
Hypercalcemia can result from many causes (Table 1). In
the general population primary hyperparathyroidism and
malignancy are by far the most common causes of hyper-
calcemia. Given our patient’s demographics, history, and
physical exam, we can eliminate many of the possibilities.
The most likely diagnoses are sarcoidosis and malignancy.
The patient had no significant history suggesting an
inherited disorder. There was also no history or findings
of paradoxical hypertension, hypotension, sweating, pal-
pitations, or tachycardia to suggest thyrotoxicosis,
pheochromocytomas, or acute adrenal insufficiency. Also,
there was no evidence to suggest an infectious granulo-
matous disease, such as fever and lymphadenopathy.
Primary hyperparathyroidism was also discounted given
the low concentration of intact parathyroid hormone.
The finding of an elevated PTHrP, as well as the lack of
excess antacid ingestion history made milk-alkali syn-
drome unikely in this patient. Hypercalcemia caused by
immobilization often manifests after four weeks of immo-
bilization, but can be seen as early as ten days2. It would
be unusual to see the degree of hypercalcemia in our
patient after immobilization for four days.
Occult sarcoidosis was initially a possibility in this patient
with pulmonary nodules, retroperitoneal mass, and hyper-
calcemia. Chest radiograph and CT of the thorax did not
reveal hilar adenopathy, though this finding would be con-
sistent with stage three disease. Sarcoidosis can present as
a focal mass anywhere in the body, and the retroperitoneal
(Continued from previous page)
Figure 1. CT Thorax without IV contrast. Note the right
pleural effusion and multiple enhancing pulmonary
nodules (arrows).
Figure 2. CT Thorax without IV contrast. Note the large
homogenous mass (arrows) in the right retroperi-
toneum involving the adrenal and kidney. It extends
into the right pleural space.
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mass could have represented this. However, 90% of
patients develop lymphadenopathy, which was not found
in this patient3. Sarcoidosis can cause hypercalcemia in
approximately 10% of patients by renal overproduction of
1,25-dihydroxyvitamin D by macrophages in sarcoid gran-
ulomas4. There have been case reports of PTHrP produc-
tion by sarcoid granulomas, but these are by far the
exception rather than the rule5. Thus while the finding of
suppressed PTH would have been expected, the finding of
elevated PTHrP in the serum was unexpected, and pointed
against a diagnosis of sarcoidosis. 
Given the serologic laboratory values for this patient, he
has humoral hypercalcemia of malignancy (HHM), which
results from secretion of a humoral factor that mimics
some or all of the effects of PTH, the most common being
PTHrP6. Aside from parathyroid carcinoma, ectopic PTH
production is extremely rare. Malignancies that are
associated with HHM include multiple myeloma,
lymphoma, renal cell cancer, squamous cell carcinomas of
any organ, transitional cell carcinoma, and ovarian cancer. 
Diseases with ectopic production of PTHrP, such as adenocar-
cinoma of the lung, squamous cell carcinoma, and renal cell
cancer, are expected to have hypercalcemia with suppressed
PTH levels, as well as low levels of 1,25-dihydroxyvitamin D
since PTHrP does not stimulate renal production of
1,25-dihydroxyvitamin D through renal 1-hydroxylase7. This
is in contrast to primary hyperparathyroidism, where high
levels of PTH and 1,25-dihydroxyvitamin D are expected.
PTHrP causes hypercalcemia by increasing bone resorption
and increasing urinary distal tubular calcium reabsorption8.
The severity of hypercalcemia should be judged by its
concentration and clinical manifestations. Since clinically
significant hypercalcemia is associated with an elevated ion-
ized calcium concentration, it is best to measure and follow
ionized serum calcium concentrations. If total serum cal-
cium measurements are used, formulas are available to
correct serum calcium concentrations for albumin levels.
Hypoalbuminemia will result in underestimation of the
severity of hypercalcemia, whereas paraproteinemia will
result in overestimation of the severity of hypercalcemia9.
Neurologic symptoms include altered mental status,
weakness, and decreased deep tendon reflexes. Mental sta-
tus changes range from decreased concentration and per-
sonality changes; to hallucinations and psychosis; to
lethargy, confusion, stupor, and coma. Localizing neuro-
logic deficits are not typical of hypercalcemia. Treatment
of hypercalcemia results in reversal of neurologic symp-
toms within several days to weeks. Unless the total serum
calcium concentration is above 14 mg/dL, or other
6
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Primary hyperparathyroidism
Sporadic (adenoma, hyperplasia, carcinoma)
Familial (isolated, cystic, MEN I/II)
Malignancy
PTHrP production
1,25 dihydroxyvitamin D production
Miscellaneous factor production (cytokines, 
growth factors)
Vitamin D disorders
Exogenous vitamin D toxicity
Endogenous vitamin D production
Williams syndrome
Granulomatous disease
Sarcoidosis
Tuberculosis
Histoplasmosis
Coccidiomycosis
Leprosy
Lymphoma
Nonparathyroid disorders
Thyrotoxicosis
Pheochromocytoma
Acute adrenal insufficiency
VIPoma
Medications
Thiazides
Lithium
Estrogens/anti-estrogens/testosterone
Milk-alkali syndrome
Vitamin A toxicity
Familial hypocalciuric hypercalcemia
Immobilization
Parenteral nutrition
Aluminum excess
Renal disease
Table 1. Differential Diagnosis of Hypercalcemia
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system manifestations of hypercalcemia are present, a
workup for mental status change should be done10.
Treatment of hypercalcemia is fourfold: correct dehydra-
tion, increase renal calcium excretion, decrease bone resorp-
tion, and correct the underlying disorder. Therapy for
hypercalcemia should always begin with infusion of saline.
The restoration of extracellular volume will aid renal excre-
tion of calcium. In addition, all diuretics should be held,
especially thiazides. Loop diuretics and ethacrynic acid
should be held until the patient is felt to be euvolemic, as
both delivery of the diuretic and calcium to the ascending
limb requires an adequate glomerular filtration rate (GFR). 
Bisphosphonates bind to hydroxyapatite in bone, prevent
its resorption, and inhibit the function of osteoclasts.
Pamidronate is commonly used at Thomas Jefferson, and
doses vary from 60 to 90 mg intravenously over 4 hours
or 24 hours. Serum calcium generally decreases to normal
levels with 5 to 7 days and remain normal for a month if
the underlying disorder is not treated. Adverse reactions
from pamidronate include low grade fever, transient
leukopenia, and nephrotoxicity from precipitated calcium
pamidronate if infused over less than 4 hours. 
Other medical therapies for acute hypercalcemia include glu-
cocorticoids plicamycin, gallium nitrate, and calcitonin.
Plicamycin and gallium nitrate are limited by their adverse
effects. Calcitonin provides rapid but short-lived reduction
of serum calcium concentration, and so is often used in urgent
situations, as well as in severe metastatic bony pain. If possi-
ble, patients should ambulate, as immobilization causes
hypercalcemia as well. In our patient it is expected that his
serum calcium will rise to hypercalcemic levels over time,
since PTHrP is not affected by calcium lowering therapy11.
Malignant tumors of the kidney account for approximately
2-3% of all cancers. Among kidney neoplasms, renal cell
carcinoma accounts for 70-85% of the total. Renal cell car-
cinoma is twice as common in males than females. The aver-
age age of diagnosis is sixty. The incidence of renal cell
carcinoma has been rising, but the cause for this increase is
not yet known. Although almost half of all cases are diag-
nosed incidentally during ultrasonography12, it is known
that the increasing incidence is not entirely accounted for
by increasing use of imaging modalities13.
Several studies have examined risk factors for developing
renal cell carcinoma. The major risk factors consistently
shown to increase risk of renal cell cancer are tobacco use
and obesity2. Risk from tobacco use is dose dependent and
declines with years of smoking cessation, such that there is
a 20-30% risk reduction after 10-15 years of cessation.
Body mass index (BMI) above the fourth quartile carries
an odds ratio of 1.1-4.6. Other factors that have inconsis-
tently been associated with renal cell cancer are hyperten-
sion, diuretic use, renal disease, and occupational exposure.
Genetic susceptibility is also a well-documented associa-
tion14. Familial forms all follow a dominant pattern of
inheritance and manifest earlier in life. Von Hippel-
Lindau (VHL) disease, tuberous sclerosis, and autosomal
dominant polycystic kidney disease (ADPKD) carry
increased risk of developing renal cell carcinoma. There
are also nonsyndromic forms of renal cell cancer that are
seen with mutations of chromosome 7, as well as translo-
cations between chromosomes 3 and 2, 6, 8, or 11.
The presentation of renal cell carcinoma is quite variable,
and has therefore been called the “internist’s tumor.”15
Signs and symptoms are often absent until the cancer has
become large or metastatic. Hematuria, abdominal pain,
and a palpable flank mass are the three most common pre-
sentations, seen in 50%, 40%, and 30% of patients,
respectively. However, the triad is only seen in 10% of
patients. Anemia and hypertension are sometimes seen as
well. Other symptoms are constitutional and nonspecific,
including fevers, sweats, weight loss, and malaise.
Obstructive phenomena may be seen, such as varicoceles
due to testicular vein obstruction. Renal cell carcinoma
may metastasize anywhere in the body. It can present as a
painless mass in the vaginal wall, or thyroid. It could also
present with visual disturbances or epistaxis from metas-
tasis to the orbit or nasal structures, respectively. 
There are numerous paraneoplastic syndromes seen in
renal cell carcinoma (Table 2)16. The presence of a parane-
oplastic syndrome does not indicate metastatic disease.
Renal cell carcinomas can produce a variety of compounds
causing the different metabolic syndromes.
Hypercalcemia is the most common metabolic syndrome
seen in renal cell carcinoma, seen in 3% of patients with
stage 1 disease, and up to 18.9% of patients with stage 4
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disease. The mechanism of hypercalcemia is production of
PTHrP by the cancer, causing bone resorption and renal
calcium reabsorption.
The diagnosis of renal cell carcinoma begins with the iden-
tification of a renal mass on an imaging study. Unless there
is strong suspicion that the renal mass is secondary to
another disease, it should be treated as malignant renal cell
cancer. After further imaging has revealed the lack of
metastatic foci, surgical resection is often recommended
because of the definite risk of metastasis if the mass were
malignant and was observed. If it is uncertain whether a
renal mass represents renal cell carcinoma or another process
such as lymphoma or recurrence of a prior cancer, percuta-
neous aspiration offers a method of diagnosis. If imaging is
suspicious for metastatic foci, some authors advocate fine
needle aspiration of metastasis to aid with staging17.
Because of the highly variable presentation and silent pro-
gression of renal cell carcinoma, only 40% of patients have
disease confined to the kidney, and up to 30% of patients
present with metastatic disease. Common sites of metas-
tasis are lung, bone, liver, adrenal, and brain, but renal
cell carcinoma may be found anywhere. Prognosis with
metastatic disease is dismal, with the survival curve
declining rapidly until 12 to 18 months, reaching a
plateau, and then slowly declining for 5 to 10 years.
As with most other cancers, the most important prognos-
tic factor in renal cell carcinoma is stage. Five year sur-
vival for stage 1 and 2 disease are 60 to 90% and 50 to
60%, respectively. Five year survival for stage 3 and 4
disease are 20 to 40% and 0 to 10%, respectively. Other
prognostic factors can be divided into tumor-related and
patient-related factors18. Other tumor-related factors
include grade and proliferative activity. Patient-related
prognostic factors include weight loss, malaise, erythro-
cyte sedimentation rate (ESR), anemia, and hypercal-
cemia. Hypercalcemia has also been shown to negatively
affect prognosis, but only in stage 4 disease19.
Though uncommon, few patients follow a different nat-
ural history than the progressive decline often seen. Some
patients experience complete remissions of varying
lengths of time, from 4 to 120 months. Up to seven per-
cent report spontaneous regression of metastases follow-
ing primary tumor resection20, although regression with-
out surgery has been reported. Spontaneous regression is
more commonly seen with lung metastases. 
Local disease is always treated with surgical resection.
Radical nephrectomy, consisting of resection of the kid-
ney, perirenal fat, and ipsilateral adrenal gland continues
to be the recommended treatment in nonmetastatic dis-
ease. Lymphadenectomy is often done to provide informa-
tion regarding local spread of the cancer. Partial
nephrectomy may be an option in patients with bilateral
renal involvement or those with an anatomically or func-
(Continued from previous page)
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Metabolic syndromes
Hypercalcemia
Renin secretion
Gonadotropin production
Prolactin production
Enteroglucagon production
Insulin production
Prostaglandin production
Hyperglycemia
Hepatic syndromes
Stauffer syndrome
Liver granulomas
Neuromuscular syndromes
Polyneuromyopathy
Polymyositis
Myopathy
Hematologic syndromes
Anemia
Erythrocytosis
Leucocytosis
Thrombocytosis
Coagulopathy
Amyloidosis
Autoimmune hemolysis
Renal syndromes
Membranous glomerulonephritis
Minimal change glomerulonephritis
Cutaneous syndromes
Dermatitis herpetiformis
Leukocytoclastic vasculitis
Hypertrichosis lanuginosa acquisita
Table 2. Paraneoplastic Syndromes
in Renal Cell Carcinoma
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tionally solitary kidney that is affected. Surgery is rarely
indicated in metastatic disease unless the goal is to
improve quality of life or treat local symptoms. 
Treatment of metastatic disease is difficult, as hormonal and
chemotherapeutic agents are ineffective. Interleukin-2 (IL-2)
is currently the only Food and Drug Administration (FDA)
approved systemic therapy for metastatic renal cell carcinoma.
However, trials with IL-2 are still ongoing. It is anticipated
that of complete responders and partial responders, 60% and
10% will remain in remission after 10 years of follow up,
respectively21,22. It must be noted that the majority of patients
did not respond to IL-2, and were exposed to the adverse
effects of IL-2. The combination of surgical and systemic med-
ical therapy remains to be studied, but preliminary results
show that a multidisciplinary approach may be justified.
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